

Nicolas Aubrey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8717959/publications.pdf>

Version: 2024-02-01

29
papers

537
citations

516710

16
h-index

642732

23
g-index

30
all docs

30
docs citations

30
times ranked

721
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening the low molecular weight fraction of human serum using ATR-IR spectroscopy. <i>Journal of Biophotonics</i> , 2016, 9, 1085-1097.	2.3	51
2	Engineering Venomâ€™s Toxin-Neutralizing Antibody Fragments and Its Therapeutic Potential. <i>Toxins</i> , 2014, 6, 2541-2567.	3.4	48
3	Design and evaluation of a diabody to improve protection against a potent scorpion neurotoxin. <i>Cellular and Molecular Life Sciences</i> , 2003, 60, 617-628.	5.4	41
4	Neurohormonal activation in severe scorpion envenomation: correlation with hemodynamics and circulating toxin. <i>Toxicology and Applied Pharmacology</i> , 2005, 208, 111-116.	2.8	40
5	Engineering of a recombinant Fab from a neutralizing IgG directed against scorpion neurotoxin Aahl, and functional evaluation versus other antibody fragments. <i>Toxicon</i> , 2004, 43, 233-241.	1.6	25
6	Targeted Delivery of <i>Toxoplasma gondii</i> Antigens to Dendritic Cells Promote Immunogenicity and Protective Efficiency against Toxoplasmosis. <i>Frontiers in Immunology</i> , 2018, 9, 317.	4.8	25
7	Using a recombinant bispecific antibody to block Na ⁺ -channel toxins protects against experimental scorpion envenoming. <i>Cellular and Molecular Life Sciences</i> , 2007, 64, 206-218.	5.4	24
8	Direct vs. mediated effects of scorpion venom: an experimental study of the effects of a second challenge with scorpion venom. <i>Intensive Care Medicine</i> , 2005, 31, 441-446.	8.2	23
9	A method to confer Protein L binding ability to any antibody fragment. <i>MAbs</i> , 2016, 8, 379-388.	5.2	23
10	Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobe. <i>Journal of Nanobiotechnology</i> , 2018, 16, 18.	9.1	21
11	Magnetic nanocarriers for the specific delivery of siRNA: Contribution of breast cancer cells active targeting for down-regulation efficiency. <i>International Journal of Pharmaceutics</i> , 2019, 569, 118572.	5.2	21
12	Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer <i>in Vitro</i> . <i>Bioconjugate Chemistry</i> , 2018, 29, 3516-3521.	3.6	20
13	Grafting of protein L-binding activity onto recombinant antibody fragments. <i>Analytical Biochemistry</i> , 2009, 388, 331-338.	2.4	19
14	Diabody Mixture Providing Full Protection against Experimental Scorpion Envenoming with Crude <i>Androctonus australis</i> Venom. <i>Journal of Biological Chemistry</i> , 2012, 287, 14149-14156.	3.4	19
15	Covalent conjugation of cysteine-engineered scFv to PEGylated magnetic nanoprobe for immunotargeting of breast cancer cells. <i>RSC Advances</i> , 2016, 6, 37099-37109.	3.6	18
16	Immunodetection of the â€™brownâ€™ spider (<i>Loxosceles intermedia</i>) dermonecrotxin with an scFv-alkaline phosphatase fusion protein. <i>Immunology Letters</i> , 2016, 173, 1-6.	2.5	16
17	A Recombinant scFv/Streptavidin-Binding Peptide Fusion Protein for the Quantitative Determination of the Scorpion Venom Neurotoxin Aahl. <i>Biological Chemistry</i> , 2001, 382, 1621-8.	2.5	14
18	Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 157, 74-84.	4.3	13

#	ARTICLE	IF	CITATIONS
19	Design and reshaping of an scFv directed against human platelet glycoprotein VI with diagnostic potential. <i>Analytical Biochemistry</i> , 2011, 417, 274-282.	2.4	12
20	A DNA Vaccine Encoding the Gn Ectodomain of Rift Valley Fever Virus Protects Mice via a Humoral Response Decreased by DEC205 Targeting. <i>Frontiers in Immunology</i> , 2019, 10, 860.	4.8	12
21	Generation of recombinant antibody fragments with toxin-neutralizing potential in loxoscelism. <i>Immunology Letters</i> , 2016, 176, 90-96.	2.5	11
22	Impact of Site-Specific Conjugation of ScFv to Multifunctional Nanomedicines Using Second Generation Maleimide. <i>Bioconjugate Chemistry</i> , 2018, 29, 1553-1559.	3.6	10
23	Loxoscelism: Advances and Challenges in the Design of Antibody Fragments with Therapeutic Potential. <i>Toxins</i> , 2020, 12, 256.	3.4	8
24	Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate. <i>European Journal of Medicinal Chemistry</i> , 2022, 229, 114063.	5.5	7
25	Exploration and Modulation of Antibody Fragment Biophysical Properties by Replacing the Framework Region Sequences. <i>Antibodies</i> , 2020, 9, 9.	2.5	4
26	Antibody Fragments Humanization: Beginning with the End in Mind. <i>Methods in Molecular Biology</i> , 2019, 1904, 231-252.	0.9	3
27	Contribution of Intrinsic Fluorescence to the Design of a New 3D-Printed Implant for Releasing SDABS. <i>Pharmaceutics</i> , 2020, 12, 921.	4.5	3
28	Engineering and Functional Evaluation of Neutralizing Antibody Fragments Against Congenital Toxoplasmosis. <i>Journal of Infectious Diseases</i> , 2021, 224, 705-714.	4.0	2
29	An effective strategy for the humanization of antibody fragments under an accelerated timeline. <i>International Journal of Biological Macromolecules</i> , 2022, 216, 465-474.	7.5	1